CA3209122A1 - Methods of making trans isomeric forms of g protein-coupled receptor modulators - Google Patents

Methods of making trans isomeric forms of g protein-coupled receptor modulators Download PDF

Info

Publication number
CA3209122A1
CA3209122A1 CA3209122A CA3209122A CA3209122A1 CA 3209122 A1 CA3209122 A1 CA 3209122A1 CA 3209122 A CA3209122 A CA 3209122A CA 3209122 A CA3209122 A CA 3209122A CA 3209122 A1 CA3209122 A1 CA 3209122A1
Authority
CA
Canada
Prior art keywords
substituted
unsubstituted
substituent group
membered
nhc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3209122A
Other languages
English (en)
French (fr)
Inventor
Cyril Bucher
James P. Davidson
Jeffrey J. Jackson
Michelle Yoo Min Ko
Grant Shibuya
David J. Wustrow
Ashkaan Younai
Mikhail ZIBINSKY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rapt Therapeutics Inc
Original Assignee
Rapt Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rapt Therapeutics Inc filed Critical Rapt Therapeutics Inc
Publication of CA3209122A1 publication Critical patent/CA3209122A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
CA3209122A 2021-02-02 2022-01-28 Methods of making trans isomeric forms of g protein-coupled receptor modulators Pending CA3209122A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163144878P 2021-02-02 2021-02-02
US63/144,878 2021-02-02
PCT/US2022/014450 WO2022169696A1 (en) 2021-02-02 2022-01-28 Methods of making trans isomeric forms of g protein-coupled receptor

Publications (1)

Publication Number Publication Date
CA3209122A1 true CA3209122A1 (en) 2022-08-11

Family

ID=80446466

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3209122A Pending CA3209122A1 (en) 2021-02-02 2022-01-28 Methods of making trans isomeric forms of g protein-coupled receptor modulators

Country Status (12)

Country Link
US (2) US12428393B2 (https=)
EP (1) EP4288425A1 (https=)
JP (1) JP2024505561A (https=)
KR (1) KR20230152027A (https=)
CN (1) CN116940564A (https=)
AU (1) AU2022216216A1 (https=)
BR (1) BR112023015472A2 (https=)
CA (1) CA3209122A1 (https=)
IL (1) IL304519A (https=)
MX (1) MX2023009053A (https=)
TW (1) TW202246236A (https=)
WO (1) WO2022169696A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5772680A (en) 1992-06-02 1998-06-30 General Surgical Innovations, Inc. Apparatus and method for developing an anatomic space for laparoscopic procedures with laparoscopic visualization

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10246462B2 (en) * 2016-09-09 2019-04-02 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
DK3743418T3 (da) * 2018-01-26 2024-09-09 Rapt Therapeutics Inc Chemokinreceptormodulatorer og anvendelser deraf

Also Published As

Publication number Publication date
TW202246236A (zh) 2022-12-01
WO2022169696A8 (en) 2023-08-31
IL304519A (en) 2023-09-01
US12428393B2 (en) 2025-09-30
AU2022216216A1 (en) 2023-08-03
CN116940564A (zh) 2023-10-24
JP2024505561A (ja) 2024-02-06
US20260092049A1 (en) 2026-04-02
MX2023009053A (es) 2023-10-16
WO2022169696A1 (en) 2022-08-11
US20220251070A1 (en) 2022-08-11
KR20230152027A (ko) 2023-11-02
BR112023015472A2 (pt) 2023-11-07
EP4288425A1 (en) 2023-12-13
AU2022216216A9 (en) 2024-05-23

Similar Documents

Publication Publication Date Title
EP3572412B1 (en) Pyridine derivative as ask1 inhibitor and preparation method and use thereof
KR102187608B1 (ko) Ssao 억제제
JP3367945B2 (ja) Orl1レセプターアゴニストとしての2−置換−1−ピペリジルベンゾイミダゾール化合物
KR102839500B1 (ko) 글리코시다제 억제제로서 유용한 피페라진 유도체의 숙시네이트 및 푸마레이트 산 부가염
BR112020018562A2 (pt) Processo preparativo
CA3062499C (en) Benzo[f]pyrido[1,2-d][1,4]oxazepine derivatives and pharmaceutical compositions thereof useful as hepatitis b virus surface antigen inhibitor
KR102549606B1 (ko) Hdac6 선택적 억제제 및 이의 제조방법과 응용
AU2018201842A1 (en) Fused ring heteroaryl kinase inhibitors
EP2424841A1 (en) Pyridinone antagonists of alpha-4 integrins
US20260092049A1 (en) Methods of making trans isomeric forms of g protein-coupled receptor modulators
JP2023505850A (ja) サイクリン依存性キナーゼ9阻害剤としての化合物及びその用途
KR102547709B1 (ko) 아제티딘 유도체
CA2758965C (en) Method for the preparation of amphiphilic imidazolinium compounds
US20170152259A1 (en) HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR
JPWO2006129626A1 (ja) [1,2,4]トリアゾロ[1,5−c]ピリミジン誘導体の製造法
WO2007082731A1 (en) Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
JPS5936674A (ja) N−置換グアニジノチアゾ−ル誘導体およびその製造法
JPH04346986A (ja) トリチウム標識化されたキサンチン誘導体
WO2024121183A1 (en) New cyanopyridine khk inhibitor compounds
Park et al. Synthesis and evaluation of tricyclic derivatives containing a non-aromatic amide as poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors
EP2411388A2 (en) Process for the production of fused, tricyclic sulfonamides
US20090118509A1 (en) Preparation of [2-methyl-5-phenyl-3-(piperazin-1-ylmethyl)] pyrrole derivatives
EA049827B1 (ru) Сукцинатные и фумаратные кислотно-аддитивные соли производных пиперазина, пригодные в качестве ингибиторов гликозидазы
JPH06505717A (ja) 新規1−アリール−4−ピペラジニル−シクロヘキサンカルボン酸ニトリル、その製造及び使用
IE41589B1 (en) Preparation of piperidine sulphonamides and intermediates thereof

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241219

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241219

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241219

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251205

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251205

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260127

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260127

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260127